Robotic-assisted transperineal fusion biopsy led to relatively low rates of prostate cancer upgrading and downgrading in a single-center study.
WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc., a global clinical-stage biotechnology company advancing next-generation ...